HCL expressing the IGHV4-34 rearrangement shares clinical features of the variant (including poorer response to purine analogs and poorer prognosis) and lacks BRAF mutation, but may be classified as classic HCL by immunophenotype [8, 11]. The gene discussed is BRAF; the disease is hairy cell leukemia.